Therapy News and Research

RSS

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

13 Jan 2014

HoLEP effective for overactive bladder symptoms

Research shows that Holmium laser enucleation of the prostate is effective in improving overactive bladder symptoms and urodynamic parameters in men with benign prostatic hyperplasia.

13 Jan 2014

Persistent insomnia symptom risk high

Insomnia symptoms are often persistent, report researchers who found that targeting sleep-interfering behaviors may be one method of prevention.

13 Jan 2014

BRAF mutation associated with other cancers appears to drive papillary craniopharyngiomas

A team led by investigators from Massachusetts General Hospital, Brigham and Women's Hospital and the Broad Institute has found that a gene mutation associated with several types of cancer also may be responsible for a rare but debilitating brain tumor called papillary craniopharyngioma.

13 Jan 2014

UMMS researchers commissioned by Alpha-1 Project to develop PiZ antibody

Researchers at the University of Massachusetts Medical School (UMMS) have been commissioned by the Alpha-1 Project (TAP) to develop a PiZ antibody. The antibody will be used to track the presence of mutant alpha-1 PiZ protein in human blood serum, an essential tool in testing potential therapies for Alpha-1 Antitrypsin Deficiency (Alpha-1).

13 Jan 2014

Scientists discover genetic signature mechanism in immune system as driving force for childhood leukaemia

Scientists have discovered a genetic signature that implicates a key mechanism in the immune system as a driving force for a type of childhood leukaemia.

13 Jan 2014

Nonsurgical treatment improves symptoms in women with pelvic floor dysfunction

One in three women suffer from pelvic floor dysfunction, a range of symptoms which include bladder and bowel problems as well as pelvic pain, according to the American Urogynecologic Society. Now, University of Missouri researchers have demonstrated that a comprehensive, nonsurgical treatment significantly improves symptoms in women with PFD.

10 Jan 2014

State highlights: Calif. Governor's budget to include $670M in new Medi-Cal spending; Mass. launches new electronic health records updates

When he unveils his new budget plan Thursday, Gov. Jerry Brown will propose billions of dollars in new spending on schools, health care, social services and environmental programs as California reaps the benefits of an economic turnaround. … The proposed budget includes $670 million more for Medi-Cal, the state's public health care program, which is expanding as part of President Obama's federal overhaul. The program is expected to serve a quarter of California's residents next year.

10 Jan 2014

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Findings of a preliminary study published in The Lancet Respiratory Medicine suggest that a patient’s own bone-marrow stromal (stem) cells could be used to treat multidrug-resistant (MDR) and extensively-drug (XDR) tuberculosis.

10 Jan 2014

Study: HIV-specific poison kills persisting HIV-infected cells during antiretroviral therapy

A team including University of North Carolina and NIH scientists has demonstrated in a mouse model that an HIV-specific poison can kill cells in which the virus is actively reproducing despite antiretroviral therapy.

10 Jan 2014

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.

10 Jan 2014

Researchers deploy potential new weapon against HIV

Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV - a combination therapy that targets HIV-infected cells that standard therapies cannot kill.

10 Jan 2014

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS.

10 Jan 2014

Researchers develop personalized tool to predict likelihood of prostate cancer overdiagnosis

Studies have found that prostate cancer is overdiagnosed in up to 42 percent of cases, prompting men to receive unnecessary treatment that can cause devastating side effects, including impotence and incontinence.

9 Jan 2014

Gastric bypass and cardiovascular disease risk: an interview with Dr. Brethauer, Cleveland Clinic

Gastric bypass surgery is a type of bariatric operation that results in weight loss and stimulates metabolic effects that treat diabetes and other cardiovascular risk factors such as diabetes, high cholesterol, and hypertension.

9 Jan 2014

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure.

9 Jan 2014

Zyomyx's MyT4 point-of-care CD4 diagnostic test receives CE mark approval

Mylan, Inc. today announced that Zyomyx's MyT4 point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, an important step toward launching this innovative test and expanding access to affordable, accessible and reliable diagnostics for people living with HIV globally.

9 Jan 2014

First Edition: January 9, 2014

Today's headlines include reports about how the politics of the health law continue to play out on Capitol Hill.

9 Jan 2014

Auxilium Pharmaceuticals reports interim data from XIAFLEX Phase 4 study in patients with DC

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord will be presented for the first time at the American Association for Hand Surgery 2014 Annual Meeting being held January 8-11, 2014 in Kauai, Hawaii.

9 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Therapy News and Research

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

HoLEP effective for overactive bladder symptoms

Persistent insomnia symptom risk high

BRAF mutation associated with other cancers appears to drive papillary craniopharyngiomas

UMMS researchers commissioned by Alpha-1 Project to develop PiZ antibody

Scientists discover genetic signature mechanism in immune system as driving force for childhood leukaemia

Nonsurgical treatment improves symptoms in women with pelvic floor dysfunction

State highlights: Calif. Governor's budget to include $670M in new Medi-Cal spending; Mass. launches new electronic health records updates

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Study: HIV-specific poison kills persisting HIV-infected cells during antiretroviral therapy

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Researchers deploy potential new weapon against HIV

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Researchers develop personalized tool to predict likelihood of prostate cancer overdiagnosis

Gastric bypass and cardiovascular disease risk: an interview with Dr. Brethauer, Cleveland Clinic

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Zyomyx's MyT4 point-of-care CD4 diagnostic test receives CE mark approval

First Edition: January 9, 2014

Auxilium Pharmaceuticals reports interim data from XIAFLEX Phase 4 study in patients with DC

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News